哪里想瘦打哪里！FDA批准Kythera服用药物上市在即

你才双下巴，你全家都双下巴！所谓爱美自始人皆有之。如果说赘肉是每一个希望占有单纯身型的“妹纸”或“汉纸”的大敌，那么一个诙谐十足的双下巴算得是这些人的生死仇敌了。每一分钟，世界各地都有人为自己的一张大饼脸而感到烦恼，虽然占有一个肉感十足的双下巴擦上去是倒是有肉感的，但是还是有很多人的身体素质使其没有背负一个双下巴之重。您可千万别恨，这甚至从未催生造出一个相当可观的市场竞争。根据美国皮肤外科手术协会的调查研究工作显示，68%的黑人对自己的双下巴问到了“心灰意冷”之情。而有鉴于此，近期Kythera母公司向FDA送交了其的机构打倒双下巴的瘦身口服式口服ATX-101。这种口服进行了许多“胖纸”梦寐以求的动态，哪里想瘦打哪里，算得是定点健美。不要以为这种近乎倔强的口服只是一个恶搞，在FDA辖下的皮肤和内科口服专员会的无记名投票当中，专家可是以17：0的超高票数相一致赞许其并购。或许是因为这些专家当中也有很多饱受双下巴之苦吧。FDA也将计划于上周的5同月13日以后对其作造出最后尽快。如果一切顺利的话，Kythera母公司计划于上周同月初将该产品线并购，分析人士原订这一口服的年销售额将超过3亿美元之多。随着瘦身口服市场竞争的逐渐减少，Kythera母公司算得是下了一步好棋。母公司于前年以8400万美元的价格从其前的公司莱曼手当中返还了这种口服的全部权利。而Kythera母公司也希望以此为契机在瘦身口服市场竞争当中渡河拔寨。就在上个同月，Kythera母公司和Actelion母公司定下价值2700万美元的合作协商，共同开发一种失败过的抑止黏膜口服，而这种口服被认为有可能开发造出一种化疗脱发的口服。详细资料英语引述：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.